| Title |
Preventive treatments for breast cancer: recent developments
|
|---|---|
| Published in |
Clinical and Translational Oncology, December 2014
|
| DOI | 10.1007/s12094-014-1250-2 |
| Pubmed ID | |
| Authors |
J. E. Alés-Martínez, A. Ruiz, J. I. Chacón, A. Lluch Hernández, M. Ramos, O. Córdoba, E. Aguirre, A. Barnadas, C. Jara, S. González, A. Plazaola, J. Florián, R. Andrés, P. Sánchez Rovira, A. Frau |
| Abstract |
Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 14% |
| Student > Doctoral Student | 3 | 11% |
| Professor | 3 | 11% |
| Student > Bachelor | 3 | 11% |
| Researcher | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 7 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 25% |
| Psychology | 3 | 11% |
| Nursing and Health Professions | 2 | 7% |
| Agricultural and Biological Sciences | 2 | 7% |
| Social Sciences | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 8 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2015.
All research outputs
#14,205,797
of 22,772,779 outputs
Outputs from Clinical and Translational Oncology
#592
of 1,296 outputs
Outputs of similar age
#191,650
of 361,258 outputs
Outputs of similar age from Clinical and Translational Oncology
#8
of 18 outputs
Altmetric has tracked 22,772,779 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,296 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,258 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.